Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Sees Large Drop in Short Interest

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) was the recipient of a large drop in short interest in the month of July. As of July 15th, there was short interest totaling 4,850,861 shares, a drop of 32.1% from the June 30th total of 7,142,803 shares. Currently, 9.1% of the company’s stock are sold short. Based on an average daily trading volume, of 947,818 shares, the short-interest ratio is currently 5.1 days.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock opened at $44.63 on Friday. The business’s 50 day simple moving average is $46.27 and its 200 day simple moving average is $49.10. Supernus Pharmaceuticals has a 52-week low of $32.83 and a 52-week high of $59.68. The firm has a market cap of $2.59 billion, a PE ratio of -87.51, a P/E/G ratio of 0.97 and a beta of 0.54.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. Cantor Fitzgerald raised their price objective on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Finally, Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $62.83.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several hedge funds have recently made changes to their positions in SUPN. Rockefeller Capital Management L.P. lifted its position in shares of Supernus Pharmaceuticals by 354.8% in the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 660 shares in the last quarter. Torren Management LLC acquired a new position in Supernus Pharmaceuticals during the fourth quarter worth $49,000. EverSource Wealth Advisors LLC bought a new position in Supernus Pharmaceuticals in the second quarter valued at $51,000. Hantz Financial Services Inc. increased its stake in Supernus Pharmaceuticals by 73.3% in the 4th quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock valued at $54,000 after buying an additional 458 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at $55,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.